IRulya Therapeutics Inc. (IRLA)
| Market Cap | 33.51M -62.9% |
| Revenue (ttm) | n/a |
| Net Income | -92.48M |
| EPS | -51.81 |
| Shares Out | 1.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 97,994 |
| Open | 30.67 |
| Previous Close | 31.62 |
| Day's Range | 30.00 - 34.40 |
| 52-Week Range | 15.10 - 909.98 |
| Beta | 1.33 |
| Analysts | Strong Buy |
| Price Target | 75.00 (+127.62%) |
| Est. Earnings | Nov 16, 2026 |
About IRLA
IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene. Its AIDE technology platform is a drug/device combination platform that uses an automated process to encapsulate a... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for IRLA stock is "Strong Buy." The 12-month stock price target is $75.0, which is an increase of 127.62% from the latest price.
News
IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference
NEW HAVEN, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapeut...
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026 Key Management changes include new CEO, Brigette Roberts, M.D.; new CFO, John Militello, CPA; and new COO Kei...
IRulya Therapeutics Slides: Corporate presentation
IRulya Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 9, 2026.
IRulya Therapeutics Transcript: EGM 2026
Stockholders preliminarily approved the PIPE-related share issuances, increase in authorized shares, and both 2026 equity plans. The adjournment proposal was not presented after proposals 1–3 received sufficient votes.
IRulya Therapeutics Proxy statement: Proxy filing
IRulya Therapeutics filed a proxy statement on October 2, 2026, providing details for shareholder voting and corporate governance matters.
IRulya Therapeutics Transcript: KOL event
LAM-001, an inhaled mTOR inhibitor, demonstrated favorable safety and efficacy signals in early PH-ILD and BOS studies, with significant improvements in exercise capacity and lung function. Upcoming phase II/III trials aim to confirm these findings and address unmet needs in severe pulmonary diseases.
IRulya Therapeutics Press release: KOL event
IRulya Therapeutics issued a press release on September 28, 2026, disclosing material business information to investors.
Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modify...
IRulya Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
LAM-001, an inhaled mTOR inhibitor, is advancing through clinical trials for BOS, PH-ILD, and SAPH, with strong KOL support and promising early data. Key readouts are expected in Q1 2027 for BOS and Q1 2028 for PH-ILD, targeting significant unmet needs in pulmonary diseases.
Quince Therapeutics to Participate in September 2026 Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modify...
IRulya Therapeutics Proxy statement: Proxy filing
IRulya Therapeutics filed a proxy statement on August 25, 2026, providing details for shareholder voting and corporate governance matters.
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline
IRulya Therapeutics Earnings release: Q2 2026
IRulya Therapeutics released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
IRulya Therapeutics Quarterly report: Q2 2026
IRulya Therapeutics has published its Q2 2026 quarterly earnings report on August 14, 2026.
IRulya Therapeutics Registration statement: Registration filing
IRulya Therapeutics filed a registration statement on August 5, 2026, providing details about a securities offering with the SEC.
IRulya Therapeutics Registration statement: Registration filing
IRulya Therapeutics filed a registration statement on July 31, 2026, providing details about a securities offering with the SEC.
IRulya Therapeutics Proxy statement: Proxy filing
IRulya Therapeutics filed a proxy statement on July 31, 2026, providing details for shareholder voting and corporate governance matters.
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifyi...
UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor),...
IRulya Therapeutics Transcript: Investor update
Announced the acquisition of Orphai and a $150M private placement to fund LAM-001, an inhaled rapamycin for multiple rare lung diseases. Phase II-A data in PH-ILD showed promising efficacy and safety, with key clinical milestones expected through 2028.
IRulya Therapeutics Press release: Investor update
IRulya Therapeutics issued a press release on May 18, 2026, disclosing material business information to investors.
IRulya Therapeutics Slides: Investor update
IRulya Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 18, 2026.
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX) announced it has acquired Orphai Therapeutics Inc., a clinical-stage biotechnology company. The a...
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor),...
IRulya Therapeutics Slides: Investor presentation
IRulya Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 17, 2026.